Wedbush Raises Price Target on Zumiez, Inc. (ZUMZ) to $18; Reiterates Neutral

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. SMCI
8. RTX
9. GOOGL
10. S

Go back to Wedbush Raises Price Target on Zumiez, Inc. (ZUMZ) to $18; Reiterates Neutral

Stifel Raises Price Target on Zumiez, Inc. (ZUMZ) to $18 Following Comp Sales Report

October 6, 2016 10:04 AM EDT

Stifel reiterated a Hold rating on Zumiez, Inc. (NASDAQ: ZUMZ), and raised the price target to $18.00 (from $17.00), following the company's September comparable sales report. Comp sales increased 6.3%, better than the consensus estimate of 2%. Management provided an improved outlook for 3Q, given the... More

William Blair Upgrades Zumiez, Inc. (ZUMZ) to Outperform

October 6, 2016 7:30 AM EDT

William Blair upgraded Zumiez, Inc. (NASDAQ: ZUMZ) from Market Perform to Outperform.

For an analyst ratings summary and ratings history on Zumiez, Inc. click here. For more ratings news on Zumiez, Inc. click here.

Shares of Zumiez, Inc. closed at $18.27 yesterday.

... More

B. Riley Upgrades Zumiez, Inc. (ZUMZ) to Buy

October 6, 2016 7:28 AM EDT

B. Riley upgraded Zumiez, Inc. (NASDAQ: ZUMZ) from Neutral to Buy with a price target of $25.00.

For an analyst ratings summary and ratings history on Zumiez, Inc. click here. For more ratings news on Zumiez, Inc. click here.

Shares of Zumiez, Inc. closed at $18.27 yesterday.

... More

After-Hours Stock Movers 10/05: (SCYX) (ZUMZ) (JD) Higher; (ALNY) (IDRA) (MDCO) Lower (more...)

October 5, 2016 6:10 PM EDT

Today's After-Hours Movers

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) 42.3% LOWER; announced that upon the recommendation of the ENDEAVOUR Phase 3 study Data Monitoring Committee (DMC) to suspend dosing, the Company has decided to discontinue development of revusiran, an investigational RNA interference (RNAi) therapeutic that was being developed for the treatment of hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM). This decision was made yesterday evening and has been communicated to investigators, study sites, and regulatory authorities.

SCYNEXIS, Inc. (Nasdaq: SCYX)... More

Zumiez, Inc. (ZUMZ) Comps Increased 6.3% in Sept.; Raises Q3 Guidance

October 5, 2016 4:02 PM EDT

Zumiez Inc. (NASDAQ: ZUMZ) announced that total net sales for the five-week period ended October 1, 2016 increased 11.5% to $75.0 million, compared to $67.3 million for the five-week period ended October 3, 2015. The Company's comparable sales increased 6.3% for the five-week period compared to a comparable sales decrease of... More